CLUEDIN
DEAD

Serial Number

98190861

Owner

Sherlock Biosciences, Inc.

Attorney

Christina S. Loza

Filing Date

Sep 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CLUEDIN Trademark

Serial Number: 98190861

CLUEDIN is a trademark filed by Sherlock Biosciences, Inc. on September 21, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Sherlock Biosciences, Inc. (5 trademarks)

Brighton, MA 02135

Entity Type: 03

Trademark Details

Filing Date

September 21, 2023

Registration Date

Not Registered

Published for Opposition

August 27, 2024

Goods & Services

Diagnostic medical testing kits comprised of chemical reagents for home medical use testing for sexually transmitted infections, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, endocrine diseases; diagnostic medical testing kits comprised of chemical reagents for medical use in prenatal testing, fetal trait testing, and gender identification testing.

Medical diagnostic testing, monitoring and reporting services; veterinary diagnostic testing, monitoring and reporting services; biomedical molecular diagnostic testing, monitoring and reporting services to aid in the diagnosis and resolution of infectious diseases, sexually transmitted infections, genetic disorders, and cancers

Medical diagnostic apparatus for testing cells, tissue, biomolecules, proteins, small molecules, and nucleotides; medical devices for obtaining bodily fluid samples; medical diagnostic instruments for the analysis of bodily fluids; medical apparatus for diagnostic use, namely, medical apparatus for diagnostic testing of health conditions, diseases, or abnormalities, in the fields of sexually transmitted infections, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and endocrine diseases; medical apparatus, devices, and instruments for prenatal testing, fetal trait testing, gender identification testing, wellness testing, health condition testing, and healthcare testing, namely, point-of-care diagnostic devices, at-home diagnostic devices, and portable health monitoring devices that detect health conditions and diseases in the nature of sexually transmitted infections, cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and endocrine diseases; medical apparatus, devices, and instruments for the detection and identification of nucleic acids

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 26, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 26, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 22, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 27, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 27, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 7, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 19, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 19, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 19, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 19, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 19, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 5, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 15, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 15, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 14, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 8, 2023 NWOS
NEW APPLICATION ENTERED
Sep 25, 2023 NWAP